While Century Therapeutics Inc has underperformed by -2.11%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IPSC rose by 20.81%, with highs and lows ranging from $5.51 to $1.28, whereas the simple moving average jumped by 43.48% in the last 200 days.
On August 28, 2023, JP Morgan Downgraded Century Therapeutics Inc (NASDAQ: IPSC) to Neutral. A report published by Chardan Capital Markets on December 27, 2022, Initiated its previous ‘Buy’ rating for IPSC. Guggenheim also rated IPSC shares as ‘Buy’, setting a target price of $15 on the company’s shares in an initiating report dated October 31, 2022. Canaccord Genuity Initiated an Buy rating on October 10, 2022, and assigned a price target of $28. H.C. Wainwright initiated its ‘Buy’ rating for IPSC, as published in its report on May 23, 2022. Piper Sandler also rated the stock as ‘Overweight’.
Analysis of Century Therapeutics Inc (IPSC)
Further, the quarter-over-quarter decrease in sales is -48.56%, showing a negative trend in the upcoming months.
One of the most important indicators of Century Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -56.07% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.92, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and IPSC is recording 220.80K average volume. On a monthly basis, the volatility of the stock is set at 9.66%, whereas on a weekly basis, it is put at 9.31%, with a loss of -12.55% over the past seven days. Furthermore, long-term investors anticipate a median target price of $14.60, showing growth from the present price of $4.18, which can serve as yet another indication of whether IPSC is worth investing in or should be passed over.
How Do You Analyze Century Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 66.58%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 27.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IPSC shares are owned by institutional investors to the tune of 27.30% at present.
